宣肺败毒方联合常规药物治疗 2019 冠状病毒病的疗效：系统评价和荟萃分析方案。
The therapeutic efficacy of Xuanfei Baidu Formula combined with conventional drug in the treatment of coronavirus disease 2019: A protocol for systematic review and meta-analysis.
机构信息
Shaanxi Academy of Traditional Chinese Medicine, Xi'an, Shaanxi, China.
Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang.
出版信息
Medicine (Baltimore). 2021 Jan 22;100(3):e24129. doi: 10.1097/MD.0000000000024129.
BACKGROUND
Coronavirus disease 2019 (COVID-19) is a new acute espiratory infectious disease that has been in a public health emergency of international concern. In China, the combination of Xuanfei Baidu Formula (XBF) and conventional drug is used in the clinical treatment of patients with new coronary pneumonia, However, there is no comprehensive and systematic evidence on the effectiveness and safety of XBF.
MATERIALS AND METHODS
We search for research in PubMed, China National Knowledge Infrastructure, Wan-fang Database, China Biomedical Database, and Chinese Science Citation Database. For "Xuanfei Baidu Formula" and "COVID-19," we screened suitable articles without language restrictions on keywords, Review Manager 5.3 and STATA 14.2 software was used for the data analysis.
RESULTS
The systematic review and meta-analysis will evaluate the efficacy and safety of XBF combined with conventional drug in the treatment of COVID-19.
CONCLUSION
We will provide evidence of XBF for the treatment on COVID-19 patients.
INPLASY REGISTRATION NUMBER
INPLASY2020120011.
背景
2019 年冠状病毒病（COVID-19）是一种新的急性呼吸道传染病，已构成国际关注的突发公共卫生事件。在中国，新型冠状病毒肺炎患者的临床治疗采用了宣肺败毒方（XBF）与常规药物联合。然而，XBF 的有效性和安全性尚无全面、系统的证据。
材料和方法
我们在 PubMed、中国知网、万方数据库、中国生物医学文献数据库和中国科学引文数据库中搜索研究。对于“宣肺败毒方”和“COVID-19”，我们对关键词没有语言限制地筛选合适的文章，使用 Review Manager 5.3 和 STATA 14.2 软件进行数据分析。
结果
系统评价和荟萃分析将评估 XBF 联合常规药物治疗 COVID-19 的疗效和安全性。
结论
我们将为 COVID-19 患者的治疗提供 XBF 的证据。
INPLASY 注册号：INPLASY2020120011。
Zotero 插件